Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 33 of 33 · 1556 articles
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...
This paper highlights potential ubiquitination-related genes and immune-cell patterns that could help researchers understand Crohn’s disease biology and point to new targets for lab validation. For patients, it signals...
Skin patches and other non‑digestive symptoms can be part of Crohn's disease and may prompt further evaluation. Knowing these signs could help people seek earlier assessment from a GP.
Researchers are trying to find blood biomarkers and a risk score that could predict who will develop Crohn’s disease before symptoms appear, which might enable earlier interventions or prevention in the future.
People with celiac disease may have higher risks for several digestive cancers and for inflammatory bowel diseases (Crohn’s and UC) according to this large French cohort study. Knowing these associations can help...
If successful, validated biomarkers and a blood risk score could allow clinicians to identify people at high risk of developing Crohn's disease and eventually test interventions to prevent symptoms. Prevention-focused...
Anal fistulas are a common and often painful complication of Crohn’s disease that usually need medical or surgical treatment. Managing the underlying Crohn’s with biologic therapy is often necessary for fistulas to heal....
This study links a specific SERPINB4 gene mutation to impaired intestinal epithelial cell function in twins with Crohn’s disease, which could help explain how rare genetic variants contribute to disease in some patients.
Understanding the differences between Crohn’s and ulcerative colitis helps patients and caregivers recognize likely symptom patterns, know which tests and treatments are commonly used, and when to seek specialist care....
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.
This announces a new FDA‑approved treatment (mirikizumab/Omvoh) for adults with moderately to severely active Crohn disease, offering another option for people who haven’t responded to prior therapies. The approval was...
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...
This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in...
At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to...
The article outlines complications of untreated Crohn’s that can become life threatening (sepsis, perforation, toxic megacolon, severe malnutrition, colorectal cancer). Knowing these risks helps people with Crohn’s...
Genetics can influence Crohn’s disease risk; knowing about risk genes and testing options may help people with a family history understand why disease runs in families and what testing can — and cannot — tell you. The...
This model aims to identify healthy first‑degree relatives at higher risk of developing Crohn’s disease before symptoms start, which could enable earlier monitoring or preventive strategies. The score uses simple...
The review brings together evidence that genetics, immune responses, the gut microbiome, and environmental triggers interact to cause Crohn's disease and ulcerative colitis.
Postoperative recurrence after ileocolonic resection is common in Crohn’s disease. This randomized trial suggests vedolizumab can reduce early endoscopic recurrence, offering an additional biologic option for preventing...
